It has been shown in pediatric patient with ABCA12-deficiency-related erythrodermic ichthyosis that, after 6 months of treatment with Secukinumab (150 mg weekly), which specifically targets IL-17, there was a 48% decrease in the Ichthyosis Area Severity Index score. This evidence concerns the gene IL17A and ichthyosis.